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We used enzymatic digestion and mass spectrometry to identify the sites of glycosylation on the SU component of the Avian Sarcoma/
Leukosis virus (ASLV) Envelope Glycoprotein (Subgroup A). The analysis was done with an SU(A)-rIgG fusion protein that binds the
cognate receptor (Tva) specifically. PNGase F removed all the carbohydrate from the SU(A)-rIgG fusion. PNGase F is specific for N-linked
carbohydrates; this shows that all the carbohydrate on SU(A) is N-linked. There are 10 modified aspargines in SU(A) (N17, N59, N80, N97,
N117, N196, N230, N246, N254, and N330). All conform to the consensus site for N-linked glycosylation NXS/T. There is one potential
glycosylation site (N236) that is not modified. Removing most of the carbohydrate from the mature SU(A)-rIgG by PNGase F treatment
greatly reduces the ability of the protein to bind Tva, suggesting that carbohydrate may play a direct role in receptor binding.
D 2004 Elsevier Inc. All rights reserved.Keywords: Avian; Retrovirus; Envelope; Glycosylation; TvaIntroduction
Retroviruses infect susceptible cells via an interaction
between the virally encoded envelope glycoproteins and
cognate receptors on the surface of the cell. This interaction
causes structural changes in the envelope glycoprotein that
lead to the fusion of the viral membrane and the cellular
membrane; membrane fusion places the viral core in the
cytoplasm of the cell. The Avian Sarcoma Leukosis Virus
(ASLV) envelope glycoproteins are a group of related
retroviral envelope glycoproteins that have been named
based on the specific receptors they interact with and their0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2004.05.020
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E-mail address: hughes@ncifcrf.gov (S.H. Hughes).reaction with antibodies. The main ASLV envelope sub-
groups are A–E. The differences in the envelopes that
allow the different ASLV envelopes to interact with their
cognate receptors map to defined segments of the envelope
(hr1, hr2, vr3) (Bova et al., 1986; Dorner et al., 1985). The
subgroup (A) receptor is Tva, a small protein of unknown
function that is related (by sequence and structure) to the
ligand binding repeat of the low-density lipoprotein recep-
tor (LDLR) (Bates et al., 1993). The B, D, and E viruses
interact with different aspects of an integral membrane
protein, originally called CAR1, now called Tvb, that is a
member of the tumor necrosis factor receptor (TNFR)
family (Adkins et al., 1997; Brojatsch et al., 1996). The
subgroup C receptor has not been identified. Appropriately
folded Tva can be expressed in soluble form; this makes it
easy to study the interactions of the envelope glycoprotein
and the receptor. Although Tvb is an integral membrane
protein, a soluble peptide (15 aa long) can substitute for
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envelope.
Retroviral envelopes (including the ASLV envelopes) are
translated from a spliced message. The proteins are glyco-
sylated and cleaved by host proteases to produce mature
proteins with two components: surface (SU) and transmem-
brane (TM). The mature protein is trimeric; TM anchors the
envelope glycoprotein in the viral membrane. TM is the
portion of the envelope that is directly involved in the fusion
of the viral membrane and the membrane of the target cell
during infection. Although the details of this fusion event
are not completely understood, major rearrangements of TM
embed the N-terminal fusion peptide of TM in the cellular
membrane and subsequent rearrangements of TM bring the
cell membrane and the viral membrane together, leading
to fusion.
The initial rearrangement of TM, in which the fusion
peptide is embedded in the membrane of the host cell,
depends on changes in the structure of SU (see Coffin et al.,
1997, for review). In the simplest mechanism, exemplified
by the Moloney Murine Leukemia Virus (MLV), when SU
binds to its cognate receptor on the surface of the cell, this
interaction triggers a change in the structure of SU, which
in turn leads to changes in the structure of TM. Human
Immunodeficiency Virus Type 1 (HIV-1) envelope interacts
with both a receptor (CD4) and a co-receptor (commonly
CXCR4 or CCR5). HIV-1 envelope interacts first with
CD4, which alters the structure of the envelope and allows
it to bind to the co-receptor. It is the interaction with the co-
receptor that triggers the critical structural change in SU
leading to the rearrangement of TM and fusion of the
cellular and viral membranes. However, for both MLV
and HIV-1, pH does not appear to play any direct role in
the events that lead to membrane fusion. In this sense, the
reactions carried out by retroviral envelopes, which are
mechanistically similar to the reactions carried out by the
HA protein of the flu virus, are differently controlled. In the
flu system, the binding of the SU-equivalent component
(HA1) to the receptor serves to bring the virus into an
acidic compartment in the cell where the pH change
triggers the change in the structure of the TM-equivalent
portion (HA2); in the MLV and HIV envelopes, it is the
binding of SU that triggers the structural change and the
virus is believed to fuse to the outer membrane of the target
cell without being transported into an acidic compartment
within the cell.
The mechanism that controls the fusion of the envelope
glycoprotein of the Avian Sarcoma/Leukosis viruses
(ASLVs) is controversial. There is good agreement that
binding the receptor to SU is an essential step, and that
there is some sort of structural change in SU when the
receptor binds. The question is whether binding is both
necessary and sufficient to trigger all the steps that lead to
membrane fusion. Mothes et al. (2000) presented evidence
that additional structural changes are required and that these
changes depend on low pH. In this model, the mechanismthat controls ASLV envelope fusion is in some ways
intermediate between the classical retroviral mechanism
(which depends only on binding the receptor to induce the
structural change) and the flu mechanism (which depends
only on low pH to induce the structural change). However,
the Mothes et al. model has been challenged; Earp et al.
(2003) have argued that low pH does not play a critical role
in ASLV envelope fusion.
For ASLV envelope, it is generally agreed that binding
the receptor at neutral pH causes a significant change in the
conformation of the protein (Damico et al., 1998; Earp et al.,
2003; Gilbert et al., 1995; Hernandez et al., 1997). This
change exposes the TM fusion peptide, which then asso-
ciates with the membrane of the target cell. The next step is
the fusion of the viral and cellular membranes, which is
associated with TM rearranging to form a stable six-helix
bundle. The controversy is whether this step does, or does
not, depend on low pH. Earp et al. (2003) have suggested
that this process proceeds, at least to the stage of hemifusion
of the membranes, at neutral pH. However, there are good
reasons to believe low pH plays a critical role in this
process.
Earp et al. (2003) suggested that some later step in the
infection process, perhaps uncoating, is pH dependent.
However, Smith et al. (2004) showed that receptor binding
and low pH are both required to cause the efficient forma-
tion of stable TM trimers; receptor binding alone produces
relatively small amounts of stable TM trimers. Melikyan et
al. (2004) presented evidence that low pH is required to
reach hemifusion of the membranes. Moreover, if HIV-1
particles carrying a Vpr-h lactamase fusion are pseudotyped
with ASLV subgroup A envelope, delivery of the viral core
into the cytoplasm is blocked by treating the cells with
NH4Cl. The effect of NH4CL on the entry of HIV-1 particles
is also seen when the particles are pseudotyped with VSV-
G, which is pH dependent. However, if HIV-1 envelope
(which is not pH dependent) is used, entry is insensitive to
NH4CL (J. Young, personal communication). These results
make the ASLV envelope glycoproteins particularly inter-
esting targets for exploring the relationship between protein
structure and membrane fusion.
Although there are partial structures for the SU compo-
nents of HIV-1 envelope and MLV envelope, there is no
corresponding information for the SU proteins of the
ASLV viruses. ASLV SU(A) is, like other retroviral SU
proteins, heavily glycosylated. As part of a larger effort to
understand the structure and function of SU(A), we phys-
ically mapped the glycosylation sites in SU(A) by a
combination of enzymatic digestion and mass spectrome-
try. This approach has been used to characterize the
glycosylation patterns of many glycoproteins, including
HIV-1 envelope (Borchers and Torme, 1999; Dell and
Morris, 2001; Leonard et al., 1990; Zhu et al., 2000). To
simplify the isolation and purification of the SU(A) pro-
tein, we used an SU(A) fused to rabbit immunoglobulin
[SU(A)-rIgG] (see Materials and methods). This fusion
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ties. The carbohydrates can be completely removed from
denatured SU(A) by PNGase F demonstrating that only N-
linked glycosylation is present. Of the 11 asparagines inFig. 1. Immunoblot and pull-down analysis of the SU(A)-rIgG and chicken sTva-m
right. The volumes (in microliters) of cell culture supernatants used and any glycos
Molecular sizes (in kilodaltons) are given on the left. (A) First, either the SU(A)-rI
rabbit agarose beads or the sTva-mIgG was immunoprecipitated with anti-mouse a
cell culture supernatant containing either the SU(A)-rIgG or sTva-mIgG protein o
separated by SDS-PAGE, and transferred to a nitrocellulose membrane. The Weste
mouse IgG, and the bound protein–antibody complexes were visualized by chem
cell culture supernatant with anti-rabbit agarose beads, and the bound complexes w
washed. The bound proteins were mixed with cell culture supernatant containing
subsequently washed. The Western immunoblot was prepared and probed as in (SU(A) that are, by sequence, sites where carbohydrates
could be attached, 10 were glycosylated. PNGase F treat-
ment of intact, unmodified SU(A)-rIgG greatly reduces its
ability to interact with Tva, suggesting that carbohydrateIgG proteins. The SU(A)-rIgG and sTva-mIgG proteins are indicated on the
idase treatment the sample received are given at the top of each immunoblot.
gG protein was immunoprecipitated from cell culture supernatant with anti-
garose beads. The bound complexes were washed and then were mixed with
r mock supernatants. After an additional wash, the proteins were denatured,
rn immunoblot was probed with peroxidase conjugated anti-rabbit and anti-
iluminescence. (B) The SU(A)-rIgG protein was immunoprecipitated from
ere washed. The samples were treated with Endo H or PNGase F and then
sTva-mIgG protein or mock supernatant, and the bound complexes were
A).
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envelope and Tva.Results
Phenotype of the SU(A)-rIgG protein
The SU(A)-rIgG fusion protein is soluble and the rabbit
IgG portion allows a simple purification of biologically active
ASLV SU(A) in good yield from chicken cells that express
the fusion protein (see Materials and methods). We have
previously demonstrated that susceptible chicken cells
expressing the SU(A)-rIgG protein are specifically resistant
to ASLV(A) infection by receptor interference but remained
susceptible to infection by other ASLV subgroups (Holmen
and Federspiel, 2000). The SU(A)-rIgG protein migrates as a
relatively compact band of approximately 82 kDa on SDS-
PAGE as determined by Western immunoblot (Fig. 1A). For
the same reasons that it is convenient to use the SU(A)-rIgG
fusion protein, it is convenient to use a corresponding fusion
protein in which Tva is linked to mouse immunoglobulin
(sTva-mIgG). This sTva-mIgG fusion has been used to
estimate that the binding affinity of chicken Tva for ASLV(A)
envelope glycoprotein expressed on chicken DF-1 cells is
approximately 0.5 nM (Melder et al., 2003). Chicken sTva-
mIgG binds the SU(A)-rIgG protein efficiently in a pull-
down assay (Fig. 1A). We treated the SU(A)-rIgG to testFig. 2. Experimental strategy for the identification of the glycosylation sites in SU
and glycosylated proteins and their proteolytic peptide fragments.whether removing the carbohydrate present on the SU(A)-
rIgG protein affected its ability to bind to sTva-mIgG. Native
SU(A)-rIgG protein was bound to agarose beads through the
IgG component and treated with either Endo H, a glycosidase
that cleaves high mannose structures from N-linked glyco-
proteins, or PNGase F, a glycosidase that cleaves N-linked
glycan chains from glycoproteins. PNGase F cleaved a
significant portion of carbohydrate from the SU(A)-rIgG
protein; after PNGase F treatment, SU(A)-rIgG migrated at
position indicating a mass of approximately 65 kDa, while
Endo H removed only a small amount of carbohydrate (Fig.
1B). The expected MW of the protein component of SU(A)-
rIgG is 62764 Da; this suggests PNGase F removes the
majority of the carbohydrate from the properly folded native
protein. The ability of the deglycosylated SU(A)-rIgG to bind
sTva-mIgG was determined using a pull-down assay. The
Endo H-treated SU(A)-rIgG was efficiently bound to the
sTva-mIgG receptor; the PNGase F-treated SU(A)-rIgG did
not bind (Fig. 1B). We conclude from these experiments that
the SU(A)-rIgG protein is biologically active and that at least
some of the N-linked carbohydrate is required for efficient
interaction with the Tva receptor.
SU(A)-rIgG analysis by mass spectroscopy
The experimental strategy for identifying the glycosyla-
tion sites in SU(A)-rIgG is depicted in Fig. 2. First, the protein
was denatured and the cysteine residues were modified.(A)-rIgG. The methodology is based on a comparison of the deglycosylated
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are thought to be involved in disulfide bonds that help define
the architecture of the protein. SU(A)-rIgG was unfolded and
the cysteines modified with acrylamide to ensure efficient
deglycosylation and proteolysis of the protein. In addition,
the peptides that contained acrylamide modified cysteines
were readily identified by mass spectrometry (MS). Matrix
assisted laser desorption/ionization time-of-flight (MALDI-
ToF) data for the full-length deglycosylated protein and MS
and MS/MS data for the proteolytic fragments indicated that
all cysteine residues were fully modified under our reaction
conditions. The total mass of the glycan modifications could
be estimated by comparing full-length glycosylated and
deglycosylated SU(A)-rIgG (Fig. 2). The individual glyco-
sylation sites in the protein were determined by comparative
MS and MS/MS analyses of proteolytic fragments derived
from the glycosylated and deglycosylated proteins.
MALDI-ToF was used to determine the MW of glycosy-
lated SU(A)-rIgG. Fig. 3A shows that the glycosylation isFig. 3. MALDI-ToF of full-length glycosylated (A, upper panel) and
deglycosylated (B, lower panel) SUA-IgG. Sinapinic acid was used as a
matrix. The glycosylated protein exhibited two major peaks at 86510 and
87612 Da indicating heterogeneous glycosylation. PNGase F treatment of
SU(A)-IgG produced a single peak with a MW of 64194 Da. This value is
within F10 Da (0.01% mass accuracy) of the calculated MW of the full-
length polypeptide chain of SU(A)-IgG, which means that PNGase F
removed all the sugar residues.somewhat heterogeneous. Two main peaks with MW of
86510 and 87612 Da were detected. Subtracting the calcu-
lated MW of the SU(A)-rIgG polypeptide chain containing
acrylamide-modified Cys residues (adding acrylamide resi-
dues to the cysteines increased the MW to 64184 Da) from
these experimental values showed that there is approximately
23 kDa of carbohydrate. The denatured SU(A)-rIgG was
treated with PNGase F, which specifically removes N-linked
carbohydrate chains. Fig. 3B shows that PNGase F-treated
SU(A)-rIgG produced a single peak of 64194 Da. This value
is within F10 Da (0.01% mass accuracy) of the calculated
MW of the SU(A)-rIgG polypeptide chain. Thus, PNGase F
treatment removed all glycans indicating that all of the
glycosylation sites in SU(A)-rIgG involve asparagine residues.
The locations of the glycosylated asparagines were
determined by subjecting glycosylated and deglycosylated
proteins to proteolysis in parallel. This generated small
peptide fragments that were used for MS/MS analyses.
The proteins were digested using trypsin, chymotrypsin,
or GluC. The peptide mixtures were analyzed with MALDI-
ToF and electrospray ionization time-of-flight (ESI-ToF)
mass spectrometry. Representative MALDI-ToF data are
shown in Fig. 4. Comparison of the peptides from glycosy-
lated and deglycosylated SU(A)-rIgG showed that some
peptide fragments were present in digests from both protein
preparations. These peptides did not contain sugar residues.
However, several proteolytic fragments were detected only
in the PNGase F-treated samples (Fig. 4A). These peptides
were generated as a result of the enzymatic removal of the
N-linked oligosaccharide and were subsequently assigned to
specific SU(A) sequences.
The deglycosylated peaks had a distinctive feature.
PNGase F treatment converts the glycosylated Asn to Asp
(plus 1 Da mass difference). We were able to detect this
difference inMWin bothMS andMS/MS analyses. Based on
nucleic acid sequence, SU(A)-derived peptides 16–24, 53–
57, 55–63, 58–79, 64–84, 68–87, 95–110, 111–134, 219–
234, and 229–241 (see Table 1) should contain a single Asn
residue; each of these fragments exhibited a mass increment
of about 1 Da associated with the Asn to Asp conversion. In
contrast, peptides 1–18, 191–202, 193–204, 219–237, and
304–332 (see Table 1) were predicted to contain two Asn
residues showed a mass difference of plus 1 Da, suggesting
that only one of the Asn residues was glycosylated. MS/MS
analyses of these peptide fragments with ESI-ToF were used
to locate the glycosylation sites. Representative MS/MS data
of chymotryptic peptide 193–204 are depicted in Fig. 5.
These data indicate that Asn196 and not Asn193 was con-
verted to Asp upon deglycosylation of the protein with
PNGase F. One chymotryptic peptide (242–270) that should
contain two Asn residues displayed a mass increment of
approximately 2 Da in MS analyses (Table 1). The MS/MS
data on this peptide confirmed that both Asn246 and Asn254
were converted to Asp upon PNGase F treatment. Thus, we
have been able to accurately identify all the glycosylated
asparagines residues in SU(A) (Table 1).
Fig. 4. Representative MALDI-ToF data of tryptic peptide fragments of deglycosylated (A, upper panel) and glycosylated (B, lower panel) SU(A)-IgG. There
are several peptide peaks present in deglycosylated protein digest but not in the glycosylated protein digest. Molecular weights of peaks 1–18, 53–67, 68–87,
and 191–202 were assigned to the corresponding peptide fragments by taking into account the 1-Da mass increment derived from Asn to Asp conversion.
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of SU(A) primary structure is given in Fig. 6. The use of three
proteolytic enzymes (trypsin, chymotrypsin, and GluC) was
complementary and enabled us to obtain greater than 92%
coverage of the amino acid sequence of SU(A). MALDI-ToF
analyses of the PNGase F-treated protein indicated that SU(A)
contained only N-linked glycans (Fig. 3). Importantly, all 16
asparagines of SU(A) were amenable to MS and MS/MS
analyses enabling us to accurately identify glycosylated and
nonglycosylated residues (Fig. 6). In SU(A), the following 10
sites are glycosylated: N17, N59, N80, N97, N117, N196,
N230, N246, N254, and N330. All of the asparagines that
carry carbohydrate conform to the consensus sequence NXS/T.
Of the 11 NXS/T sites in SU(A), 1 (N236) is not glycosylated.Discussion
Mass spectrometry shows that SU(A)-rIgG contains
approximately 23 kDa of carbohydrate. All the carbohydrate
is N-linked. There are 11 potential N-linked glycosylation
sites in SU(A); 10 of the 11 sites have a carbohydratemodification. The one potential N-linked glycosylation site
that is not modified in SU(A) is N236. The S at 238 can be
mutated to A (which would have blocked glycosylation of
N236 had it been a site for glycosylation) without causing
serious disruption in the structure or function of SU(A).
Virus carrying the S238A mutation in SU(A) retained 37%
of wild-type infectivity (Delos et al., 2002).
Mutating the S or T residues just downstream of three of
the N-linked glycosylation sites in SU(A) (N59, N196, and
N254) affected the folding and processing of SU(A) (Delos et
al., 2002). Multiple mutations at other S or T residues
associated with other glycosylation sites also had deleterious
effects on SU(A). However, the mutagenesis experiments and
our PNGase F digestion experiments ask somewhat different
questions. The mutagenesis experiments showed which sites
(more specifically the S or T residues in these sites) are
essential. These sites may, or may not, be sites where there is
an essential carbohydrate. The effects of the SU(A) mutations
may not be a direct effect of blocking glycosylation; the
primary effect of the mutations might involve the folding and
processing of the protein. Our PNGase F experiments involve
the removal of carbohydrate from a mature, properly folded
Table 1
Summary of deglycosylated peptides identified with ESI-ToF MS and MS/MS
Exp. peptide mass
(charge state)
Mr exp.
(Da)
Mr calc.
(Da)
Delta
(Da)
Amino acid sequencea
Chymotryptic peptides
505.72 (2+) 1009.44 1008.46 0.98 16-A(N/D)RTGQTDF-24
1025.45 (1+) 1024.45 1023.46 0.99 55-VSDT(N/D)C*TTL-63
1056.47 (2+) 2110.94 2109.98 0.94 64-GTDRLVSSADFTGGPD(N/D)STTL-84
956.97 (2+) 1911.94 1910.98 0.97 95-KL(N/D)VSMWDEPPELQLL-110
1203.59 (2+) 2405.19 2404.21 0.98 111-GSQSLP(N/D)ITNIAQISGITGGC*VGF-134
767.85 (2+) 1533.70 1532.66 0.94 193-NMY(N/D)C*SQVGRQY-204
761.32 (2+) 1520.64 1519.68 0.94 229-V(N/D)QSQEINESEPF-241
1015.82 (3+) 3044.46 3042.45 2.01 242-SFTV(N/D)C*TASSLG(N/D)ASGC*C*GKAGTILPGKW-270
Tryptic peptides
1082.03 (2+) 2162.06 2161.11 0.95 1-DVHLLEQPGNLWITWA(N/D)R-18
837.84 (2+) 1673.68 1672.74 0.94 53-GYVSDT(N/D)C*TTLGTDR-67
1051.98 (2+) 2101.96 2101.00 0.96 68-LVSSADFTGGPD(N/D)STTLYTYR-87
788.82 (2+) 1575.65 1574.68 0.97 191-FWNMY(N/D)C*SQVGR-202
388.21 (2+) 774.42 773.44 0.98 327-VLV(N/D)SSR-333
GluC peptides
767.37 (3+) 2299.11 2298.05 1.06 58-T(N/D)C*TTLGTDRLVSSADFTGGPD-79
654.65 (3+) 1960.95 1959.98 0.97 219-IQC*TRRGGKWV(N/D)QSQE-234
773.38 (3+) 2317.14 2316.15 0.99 219-IQC*TRRGGKWV(N/D)QSQEINE-237
a N/D conversion identified by MS/MS.
*Cysteine modified with acrylamide.
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in binding SU(A) to Tva.
What is surprising is not that carbohydrate could have a
role in binding Tva, but that all asparagines that carry the
carbohydrate in SU(A) are conserved in the various ASLVFig. 5. Representative MS/MS data of a chymotryptic peptide. The amino acid seq
peptide yielded only a 1 Da increment, indicating that only one of the two Asn was
Asn196 and not Asn193 was converted to Asp. ‘‘y’’ and ‘‘b’’ ions correspond to p
peptide, respectively. The molecular weight difference between y7 and y8 corresenvelope subgroups. This suggests that the various ASLV
SU proteins will have a common pattern of carbohydrate
modification. This makes good sense if the carbohydrate
plays a structural role; however, it does raise a question:
Why would a carbohydrate group that is present in all theuence from 255 to 266 of SU(A) contains two Asn residues. MS data of this
converted to Asp upon the PNGase F treatment. The MS/MS data show that
eptide fragmentation products generated from the C and N terminus of the
ponded to acrylamide modified cysteine (depicted as C* in the figure).
Fig. 6. Summary of MS and MS/MS analyses of the proteolytic fragments in relation to the SU(A) primary structure. The proteolytic peptides that were
identified by MALDI-ToF and ESI-ToF are underlined. The glycosylation sites are indicated. The variable regions (vr1, vr2, vr3, hr1, and hr2) are highlighted.
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particular receptor, Tva? It is possible that Tva was
selected, evolutionarily, as a receptor for ASLV, because
it interacts with conserved elements of ASLV envelope. It
is likely that an ancestral ASLV envelope, which presum-
ably recognized one receptor, gave rise to the current
diverse set of envelopes that recognize several distinct
receptors. This means that the parental envelope must
have acquired the ability to recognize additional receptors.
Such an event would be favored if there was some
interaction between the basic envelope structure and the
novel receptor. Mutations in the variable regions of the
envelope that play a specific role in receptor recognition
(hr1, hr2, vr3) would enhance any basic interaction and
bring about the high-affinity interactions that are charac-
teristic of the interactions of a retroviral envelope and its
receptor. This type of scenario suggests, when envelope
evolves the ability to use a new receptor, that not all the
proteins on the surface of the host are equally likely to be
chosen as targets. Rather, there would be a strong proba-
bility that the protein chosen as a receptor would be a
protein for which the parental envelope would already
have a modest affinity, which could explain why a carbo-
hydrate that appears to be conserved would interact with a
specific receptor.
There are alternative possibilities: Delos et al. (2002)
suggested that the presence of carbohydrate plays a critical
role in properly positioning one of the variable loops of
SU(A). When Delos et al. (2002) mutated the S or T
residues just downstream of the glycosylated asparagines
glycosylation sites one at a time, three sites had a major
effect on protein expression and folding (N59, N196, and
N254). Of these, only the N254 mutant produced enoughprotein to assay; the mutant protein bound Tva poorly, and
Delos et al. (2002) suggested that the carbohydrate at this
position might be important, although this site is relatively
far [on the linear amino acid sequence of SU(A)] from any
of the variable regions associated with binding to specific
receptors (hr1, hr2, vr3). If proximity to a variable region is
important in the proper positioning of one of the variable
segments that interact with specific receptors, N196 is quite
close to hr2. It is also possible that one of the functions of
the carbohydrate is to shield the charged amino acids
(originally Asn, converted to Asp by PNGase F) to which
the carbohydrate is linked. In such a model, the exposure of
charged residues on the surface of SU(A) could affect its
interaction with Tva. This type of model would suggest that
the function(s) of the carbohydrate on SU(A) do not depend
on any single site having carbohydrate modification but
rather on the modification of several of the carbohydrate
groups on SU(A). If this is the case, the loss of any one
individual carbohydrate group would not be critical; how-
ever, removing several of the carbohydrate groups could
significantly impair Tva binding.Materials and methods
Vector constructions and cell culture
SU(A)-rIgG is a fusion of the Schmidt–Ruppin A Rous
sarcoma virus SU glycoprotein with a portion of the
constant region of a rabbit IgG (Zingler and Young,
1996). The protein was produced from TF/SU(A)-19 cells,
a clonal DF-1 chicken cell line that constitutively expresses
SU(A)-rIgG, as described previously (Holmen and Feder-
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receptor, sTva-mIgG, a fusion of the extracellular domain of
the chicken Tva receptor with a portion of the constant
region of a mouse IgG (Holmen et al., 2001), was produced
from TF/cksTva-15 cells, a clonal DF-1 cell line that
constitutively expresses chicken sTva-mIgG, as described
previously (Melder et al., 2003). Both the TF/SU(A)-19 and
TF/cksTva-15 cells were routinely grown in Dulbecco’s
modified Eagle’s medium [DMEM (GIBCO/BRL)] supple-
mented with 10% fetal bovine serum (GIBCO/BRL), 100
units of penicillin per milliliter and 100 Ag of streptomycin
per milliliter (Quality Biological, Inc, Gaithersburg, MD),
and 250 Ag of G418 per milliliter (GIBCO/BRL) at 39 jC
and 5% CO2.
Immunoprecipitations and pull-down assays
The SU(A)-rIgG protein was immunoprecipitated from a
500-Al aliquot of TF/SU(A)-19 cell culture supernatant with
50 ml of anti-rabbit IgG-agarose beads (Sigma) for z1 h at
4 jC. The chicken sTva-mIgG protein was immunoprecipi-
tated from a 500-Al aliquot of TF/cksTva-15 cell culture
supernatant with 50 Al of anti-mouse IgG-agarose beads
(Sigma) for z1 h at 4 jC. The protein–antibody agarose
bead complexes were collected by centrifugation and
washed twice in dilution buffer [50 mM Tris-buffered saline
(TBS), 1% Triton X-100, 1 mg/ml BSA], once in 50 mM
TBS and once in 0.05 M Tris–Cl, pH 6.8. The washed
complexes were collected by centrifugation, resuspended in
50 Al Laemmli sample buffer (2% SDS, 10% glycerol,
0.0625 M Tris–Cl, pH 6.8, 0.1% bromophenol blue, 5%
h-mercaptoethanol), and heated for 5 min at 100 jC. The
samples were centrifuged for 2 min and the supernatants
were transferred to fresh tubes.
The sTva-mIgG receptor with SU(A)-rIgG anti-rabbit
agarose complexes or the SU(A)-rIgG ligand with sTva-
mIgG anti-mouse agarose complexes were also used in
pull-down assays. Cell culture supernatants containing the
receptor or ligand were incubated with the washed
protein–antibody agarose bead complexes for >1 h at 4
jC, washed and processed as above. For some experi-
ments, the native SU(A)-rIgG bound to the anti-rabbit
agarose beads was deglycosylated with Endo H (New
England Biolabs) in the supplied G5 reaction buffer or
PNGase F (New England Biolabs) in the supplied G7
reaction buffer. Standard reactions (100-Al reaction vol-
ume) contained 500 units of enzyme and were incubated
for 3 h at 37 jC.
Western transfer analysis
The denatured immunoprecipitates were fractionated by
SDS-PAGE (12% polyacrylamide) and transferred to a
nitrocellulose membrane. The filters were blocked with
10% nonfat dry milk (NFDM) in PBS, and probed with
0.05 Ag/ml peroxidase-conjugated goat anti-mouse IgG or0.05 Ag/ml peroxidase-conjugated goat anti-rabbit antibod-
ies (Kirkegaard and Perry Laboratories, Gaithersburg, MD)
in rinse buffer (10 mM Tris–Cl, pH 8.0, 100 mM NaCl, 1
mM EDTA, 0.1% Tween 20, and 1% NFDM), and washed
in rinse buffer. Protein–antibody complexes were detected
with the Western Blot Chemiluminescence Reagent (NEN)
according to the manufacturer’s instructions. The immuno-
blot was then exposed to Kodak X-Omat film.
Expression and purification of SU(A)-rIgG
TF/SU(A)-19 cells were grown to confluence in normal
growth media. Twenty-four hours before the SU(A)-rIgG
protein was collected for purification, the media on conflu-
ent TF/SU(A)-19 cells was replaced with serum-free
DMEM without supplements. The culture supernatants were
harvested, filtered through a 0.45-Am filter, and stored at
80 jC. Fresh media was added to the cultures, and after an
additional 24 h, supernatant was harvested a second time
and processed as described above. Under these conditions,
the cell supernatants contained an average of 650 ng SU(A)-
rIgG per milliliter.
Five liters of cleared supernatant was concentrated ap-
proximately 50-fold by filtration on a 30-kDa cutoff tan-
gential flow membrane (Vivaflow). The concentrated
sample was diluted 5-fold with dilution buffer (50 mM Tris,
pH 8.3, 150 mM NaCl) and reconcentrated two times. The
concentrated and washed sample was then applied to a
1.0-ml Protein A column (Pharmacia) equilibrated with
dilution buffer. The loaded column was washed with 30
ml dilution buffer followed by 30 ml of 10 mM Tris, pH 8.0.
The sample was eluted from the column with 100 mM
glycine, pH 3.0, into tubes that contained 100 Al 2 M Tris,
pH 8.3. Peak fractions were pooled and concentrated using
two 3-ml 10K cutoff centrifugal concentration units (Fil-
tron). Samples were diluted to 10 ml with 20 mM Hepes, pH
7.4, containing 500 mM NaCl, and reconcentrated three
times. The sequence of the N terminus of the purified
SU(A)-rIgG was determined by the Mayo Clinic Protein
Core Facility using Edman degradation performed with a
Applied Biosystems cLC492 Protein Sequencer. Analysis of
the purified SU(A)-rIgG allowed the assignments of the first
11 amino acids: DVHLLEQPGNL, which corresponds to
the expected sequence of mature ASLV(A) SU.
Reduction and acrylamide modification of cysteines
The cysteine modification was performed according to a
procedure described previously (Brune, 1992). Briefly,
SU(A)-rIgG was incubated in 0.3 M Tris–HCl, pH 8.3,
containing 2% SDS and 0.1 M DTT at 65 jC for 30 min.
The mixture was cooled to 37jC and incubated with 2 M
acrylamide for 30 min. The modified protein was precipi-
tated with cold acetone and dried under vacuum during
centrifugation. At this stage, samples were divided into two
parts. One part was directly subjected to HPLC purification
M. Kvaratskhelia et al. / Virology 326 (2004) 171–181180while another part was deglycosylated before the HPLC
purification step.
Deglycosylation of SU(A)-rIgG with PNGase F
Modified SU(A)-rIgG was resuspended in 50 mM
Na3PO4, pH 7.5, containing 0.1% SDS and 2% h-mercap-
toethanol and denatured at 95 jC for 5 min. The samples
were allowed to cool to 37 jC, then Triton X-100 (1% final
concentration) and 500 Units of PNGase F (New England
BioLabs) were added to the sample and the reaction was
incubated at 37 jC for 1 h. The deglycosylated protein was
precipitated with cold acetone and dried under vacuum
during centrifugation.
HPLC purification of proteins
Glycosylated and deglycosylated protein samples were
purified separately following the procedure described below.
The dried samples were first suspended in 80 Al of 6 M
guanidinium hydrochloride solution at 37 jC for 30 min.
Subsequently, 20 Al of an aqueous solution of 2% acetonitrile
and 1% formic acid was added and the mixture was centri-
fuged at 5000  g for 10 min. The supernatant was then
injected into a phenyl reverse phase column (TOSOH). The
protein was eluted with a 40-ml linear gradient of 2–90%
acetonitrile in an aqueous solution of 1% formic acid. The
elution profile was monitored by UV absorbance at 280 nm.
Proteolytic digestion of SU(A)-rIgG
HPLC purified SU(A)-rIgG containing fractions were
pooled and desiccated. The proteolytic digestions contained
5 Ag of SU(A)-rIgG and 0.5 Ag of one of the following three
proteases: trypsin, chymotrypsin, or GluC (Roche). Trypsin
digestion was carried out in 50 mM ammonium-bicarbonate
buffer at 37 jC for 16 h. Chymotryptic digestion of the
protein was performed in 10 mM Tris–HCl buffer, pH 7.8,
at 25 jC for 16 h. GluC digestion was carried out in 50 mM
ammonium-acetate, pH 4.0, at 25 jC for 16 h. The proteo-
lytic fragments were dried under vacuum during centrifu-
gation and resuspended in aqueous solution of 0.1%
trifluoroacetic acid.
Mass spectrometric analyses
MS analyses yield accurate molecular weight measure-
ments of proteins and peptides, while MS/MS analyses
provide amino acid sequence information for small-molec-
ular-weight peptides (MW less than 4 kDa) based on
internal fragmentation of peptide bonds. MS spectra were
recorded using MALDI-ToF or quadripole time-of-flight
(Q-ToF) techniques. MALDI-ToF experiments were per-
formed with Kratos Axima-CFR instrument (Kratos Ana-
lytical Instruments, Manchester, UK). HPLC purified
fractions of glycosylated and deglycosylated SU(A)-rIgGwere mixed with equal volumes of a saturated sinapinic acid
solution in 50% acetonitrile in water and applied on the
MALDI sample plate. The proteolytic peptide fragments of
SU(A)-rIgG were analyzed using a-cyano-4-hydroxy-cin-
namic as a matrix.
MS and MS/MS analyses of the proteolytic peptides
were carried out using a Micromass (Manchester, UK)
Q-ToF-II instrument equipped with an electrospray source
and a Micromass cap-LC. Peptides were separated with the
Thermo Hypersil Keystone 72105-030315 precolumn
(Thermo Environmental, Franklin, MA) and the Micro-Tech
Scientific (Vista, CA) ZC-10-C18SBWX-150 column using
two sequential linear gradients of 5–40% acetonitrile for 35
min and 40–90% acetonitrile for 10 min. MS/MS analysis
data and the MASCOT search engine , www.matrixscience.
com) were used to identify SU(A) peaks from the NCBInr
primary sequence database.Acknowledgments
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